1. Home
  2. OCGN vs UIS Comparison

OCGN vs UIS Comparison

Compare OCGN & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • UIS
  • Stock Information
  • Founded
  • OCGN 2013
  • UIS 1942
  • Country
  • OCGN United States
  • UIS United States
  • Employees
  • OCGN N/A
  • UIS N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • UIS EDP Services
  • Sector
  • OCGN Health Care
  • UIS Technology
  • Exchange
  • OCGN Nasdaq
  • UIS Nasdaq
  • Market Cap
  • OCGN 278.3M
  • UIS 271.5M
  • IPO Year
  • OCGN N/A
  • UIS N/A
  • Fundamental
  • Price
  • OCGN $1.06
  • UIS $4.14
  • Analyst Decision
  • OCGN Strong Buy
  • UIS Hold
  • Analyst Count
  • OCGN 3
  • UIS 1
  • Target Price
  • OCGN $6.00
  • UIS $6.50
  • AVG Volume (30 Days)
  • OCGN 6.3M
  • UIS 612.4K
  • Earning Date
  • OCGN 08-07-2025
  • UIS 08-04-2025
  • Dividend Yield
  • OCGN N/A
  • UIS N/A
  • EPS Growth
  • OCGN N/A
  • UIS N/A
  • EPS
  • OCGN N/A
  • UIS N/A
  • Revenue
  • OCGN $4,522,000.00
  • UIS $1,952,700,000.00
  • Revenue This Year
  • OCGN N/A
  • UIS N/A
  • Revenue Next Year
  • OCGN N/A
  • UIS $3.79
  • P/E Ratio
  • OCGN N/A
  • UIS N/A
  • Revenue Growth
  • OCGN N/A
  • UIS N/A
  • 52 Week Low
  • OCGN $0.52
  • UIS $3.32
  • 52 Week High
  • OCGN $1.98
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 59.49
  • UIS 41.35
  • Support Level
  • OCGN $1.10
  • UIS $4.41
  • Resistance Level
  • OCGN $1.29
  • UIS $5.08
  • Average True Range (ATR)
  • OCGN 0.10
  • UIS 0.19
  • MACD
  • OCGN -0.00
  • UIS -0.06
  • Stochastic Oscillator
  • OCGN 53.06
  • UIS 8.98

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

Share on Social Networks: